We are representing Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held orthopaedic medical device company dedicated to improving the quality of life of patients with osteoarthritis, cartilage damage and other musculoskeletal conditions, for $435 million. Cartiva focuses on treatment of osteoarthritis of the great toe. The transaction is expected to be completed in the fourth quarter of 2018, and is subject to regulatory approval and customary closing conditions.
Bass, Berry & Sims PLC is serving as lead counsel on the transaction. JP Morgan Securities, LLC is serving as financial advisor on the transaction
Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.